A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec
About the study
Who can take part
INCLUSION CRITERIA
Key Inclusion Criteria:
For all participants:
- Genetic documentation of 5q SMA homozygous gene survival motor neuron 1 (SMN1) deletion or mutation, or compound heterozygous mutation
- SMN2 copy number of ≥1
- ≤36 months of age at the time of first Nusinersen dose
- Must have previously received onasemnogene abeparvovec per the approved label or local/regional regulations ≥2 months prior to first Nusinersen dose
- Must have suboptimal clinical status per the Investigator
Additional Criteria for Subgroups A and B:
- ≤9 months of age (270 days) at the time of first Nusinersen dose
- SMN2 copy number of 2
Additional Criteria for Subgroup A:
- SMA symptom onset ≤4 months (120 days) of age
- Must have received intravenous (IV) onasemnogene abeparvovec at >6 weeks to ≤6 months (43 days to 180 days) of age
- Must have received IV onasemnogene abeparvovec after SMA symptom onset
Additional Criteria for Subgroup B:
Must have received IV onasemnogene abeparvovec at ≤6 weeks (42 days) of age
EXCLUSION CRITERIA
Key Exclusion Criteria:
For all participants:
- Prior exposure to Nusinersen
- Ongoing severe or serious AEs related to onasemnogene abeparvovec
- Treatment with an investigational drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to study; any prior or current treatment with any survival motor neuron 2 (SMN2)-directed splicing modifier; prior antisense oligonucleotide treatment or cell transplantation; gene therapy for the treatment of SMA other than onasemnogene abeparvovec. Note: treatment with onasemnogene abeparvovec as part of an investigational study is allowed
Additional Criteria for Subgroups A and B:
Weight-for-age is below the third percentile, based on WHO Child Growth Standards at the time of receiving onasemnogene abeparvovec. Adjustments for the gestational weight of premature babies enrolled in Subgroups A and B are allowed provided IV onasemnogene abeparvovec was dosed per the approved label or per local/regional regulations.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Study’s details
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?